Pancreatic adenocarcinoma secretome as a dynamic biomarker for patient stromal reprogramming efficacy

胰腺癌分泌组作为患者基质重编程功效的动态生物标志物

• 批准号: 10663380
• 负责人: Paul Michael Campbell
• 金额: $ 9.4万
• 依托单位: RESEARCH INST OF FOX CHASE CAN CTR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-08 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10663380
• 关键词: Address; Adjuvant Chemotherapy; Affect; Biological Markers; Biological Specimen Banks; Blood specimen; Cancer Etiology; Cells; Cessation of life; Chemotherapy and/or radiation; Clinical; Clinical Trials; Combination Drug Therapy; Companions; Consent; Cyst Fluid; DNA; Desmoplastic; Doctor of Philosophy; Duct (organ) structure; Early Diagnosis; Environment; Epithelial Cells; Epithelium; Excision; FDA approved; Fibroblasts; Fibrosis; Fox Chase Cancer Center; Future; Goals; Hydroxychloroquine; Immune; Immunosuppression; Inflammatory; Knowledge; Laboratories; Language; Letters; Liquid substance; Losartan; Macrophage; Malignant Neoplasms; Malignant neoplasm of pancreas; Measurement; Measures; Mediator; Methodology; Methods; MicroRNAs; Modality; Modeling; Monitor; Natural Killer Cells; Neighborhoods; Neoadjuvant Therapy; Operative Surgical Procedures; Outcome; Pancreas; Pancreatic Adenocarcinoma; Pancreatic Cyst; Pancreatic duct; Pancreatitis; Paracrine Communication; Patients; Pharmaceutical Preparations; Pilot Projects; Preparation; Prior Therapy; Protocols documentation; RNA; Radiation; Radiation therapy; Reaction; Recovery; Resistance; Sampling; Signal Transduction; Solid Neoplasm; Stromal Cells; Stromal Neoplasm; Surface; Testing; Therapeutic; Therapeutic Intervention; Time; Tissues; Tumor Markers; Untranslated RNA; Work; cancer cell; cancer therapy; chemokine; chemoradiation; chemotherapy; clinical trial enrollment; cohort; cytokine; design; effective therapy; exosome; extracellular vesicles; feasibility testing; innovation; neoplastic cell; novel; novel therapeutics; pancreatic cancer patients; pancreatic juice; pancreatic neoplasm; paracrine; paricalcitol; patient biomarkers; peripheral blood; phase I trial; programs; response; standard of care; therapeutic target; treatment response; tumor; tumor growth; tumor microenvironment; tumor progression

PROJECT SUMMARY/ABSTRACT Pancreatic cancer is predicted to soon become the second leading cause of cancer deaths in the USA. For the few patients diagnosed early, surgery is the best option, yet surgery alone is rarely curative. Hence, preoperative chemotherapy plus radiotherapy have a potential of increasing the possibility for long-term survival. A unique hallmark of pancreatic cancer is “desmoplasia”; pancreatic cancer’s non-tumor cells expansion & fibrosis. Cancer cells modify the local neighborhood cells (i.e., desmoplasia or stroma) in a way that these promote, instead of normally restrict, tumor growth via specific cancer associated fibroblastic cells (CAFs). At the Fox Chase Cancer Center Marvin & Concetta Greenberg Pancreatic Cancer Institute, extensive prior work has established the key relationship between the pancreatic neighborhood, the neoadjuvant-generated local fibrosis, & patient survival. When the neighborhood cells (including CAFs, immune & other cells) are altered by the epithelial cells and/or by preoperative therapy, this local reaction may engage therapy resistance. Understanding this relationship is key in treating pancreatic cancer & effective therapy must be aimed at “normalization” of the neighborhood cells to return its natural tumor suppressive activity. What is poorly understood is the impact of the various paracrine mediators that act as the language between epithelial tumor cells, CAFs, immune cells, and other constituents of the tumor. Further, a gap in our knowledge exists for our understanding of which chemokines & cytokines are influenced by neoadjuvant therapy in pancreatic cancer. In this study we will determine the changes in tumor-neighborhood secretome signaling players associated with preoperative therapy. The study proposes to test the feasibility of monitoring the secretory changes subsequent to a new therapy intervention, implemented after chemo/radiation & before surgery, aimed to reprogram the stroma and its interactions. We will take advantage of the 4-6 week waiting period before surgery, as a “Window of Opportunity,” to test three microenvironment “normalizing” drugs (PHL: paricalcitol, hydroxychloroquine, & losartan) with demonstrated excellent tolerability for each in pancreatic cancer patients receiving chemotherapy. In this phase I trial, we will establish the feasibility for quantifying the effect of the total neoadjuvant therapy/PHL combination on the pancreas secretome as measured by inflammatory & proliferative chemokine & cytokines in pancreatic juice. Establishing a paradigm for “window of opportunity” sampling will allow us to assess our ability to influence the “neighborhood normalizing” hypothesis at the secretome level. Ultimately, this study will serve as a model to treat & monitor in real-time the efficacy for subsequent patients as well as to test new promising therapies in future pancreatic cancer “window of opportunity” trials.

项目摘要/摘要 胰腺癌预计很快将成为美国癌症死亡的第二大原因。对于 早期诊断的患者很少，手术是最好的选择，但单靠手术很少治愈。因此，在手术前 化疗加放射治疗有可能增加长期生存的可能性。独一无二的 胰腺癌的特点是“结缔组织增生”；胰腺癌的非肿瘤细胞扩张和纤维化。癌 细胞以一种促进而不是促进间质的方式修改本地邻近的细胞(即促结缔组织增生或间质) 通常通过特定的癌症相关成纤维细胞(CAF)来限制肿瘤的生长。在狐狸追逐癌症 Marvin&Concetta Greenberg胰腺癌研究所，广泛的前期工作已经确立了关键 胰腺邻近、新佐剂引起的局部纤维化和患者生存之间的关系。 当邻近细胞(包括CAF、免疫细胞和其他细胞)被上皮细胞和/或 术前治疗时，这种局部反应可能会引起治疗抵抗。理解这种关系是关键 胰腺癌的有效治疗必须以邻近细胞的“正常化”为目标 恢复其天然的肿瘤抑制活性。人们对各种旁分泌的影响知之甚少。 在上皮性肿瘤细胞、CAF、免疫细胞和其他成分之间充当语言的介体 肿瘤的组织结构。此外，我们对哪些趋化因子和细胞因子的理解存在差距。 新辅助治疗对胰腺癌的影响。 在这项研究中，我们将确定与肿瘤相关的邻近分泌体信号玩家的变化。 进行术前治疗。这项研究建议测试监测分泌变化的可行性 在化疗/放疗后和手术前实施的新的治疗干预措施之后，旨在 对基质及其相互作用进行重新编程。 我们将利用手术前4-6周的等待期，作为测试的机会之窗 三种微环境“正常化”药物(苯丙氨酸钙、羟氯喹和氯沙坦) 在接受化疗的胰腺癌患者中，每种药物都表现出极好的耐受性。在这个阶段 I试验，我们将建立量化完全新辅助治疗/PHL联合治疗效果的可行性 胰腺内炎性和增殖性趋化因子及细胞因子对胰腺分泌体的影响 果汁。建立一个“机会之窗”抽样的范例将使我们能够评估我们的影响能力 秘密层面的“邻里关系正常化”假说。最终，这项研究将起到示范作用。 实时治疗和监测后续患者的疗效，并测试新的有希望的治疗方法 未来胰腺癌的“机会之窗”试验。